Menu
Search
|

Menu

Close
X

Karyopharm Therapeutics Inc KPTI.OQ (NASDAQ Stock Exchange Global Select Market)

12.27 USD
-0.25 (-2.00%)
As of Oct 19
chart
Previous Close 12.52
Open 12.59
Volume 139,927
3m Avg Volume 228,899
Today’s High 12.84
Today’s Low 12.17
52 Week High 21.69
52 Week Low 9.00
Shares Outstanding (mil) 60.56
Market Capitalization (mil) 941.76
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.90 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
30
FY17
2
FY16
0
FY15
0
EPS (USD)
FY18
-1.375
FY17
-2.807
FY16
-2.934
FY15
-3.317
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
29.97
6.55
Price to Book (MRQ)
vs sector
4.41
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
0.00
14.15
LT Debt to Equity (MRQ)
vs sector
0.00
11.31
Return on Investment (TTM)
vs sector
-73.04
12.83
Return on Equity (TTM)
vs sector
-74.59
14.95

EXECUTIVE LEADERSHIP

Sharon Shacham
President, Co-Founder, Chief Scientific Officer, Since 2017
Salary: $435,000.00
Bonus: $171,856.00
Michael Kauffman
Co-Founder, Chief Executive Officer and Director, Since
Salary: $530,500.00
Bonus: $251,503.00
Michael Falvey
Chief Financial Officer, Executive Vice President, Treasurer, Since 2017
Salary: --
Bonus: --
Christopher Primiano
Executive Vice President, Chief Business Officer, General Counsel and Secretary, Since 2017
Salary: $390,000.00
Bonus: $133,770.00
Anand Varadan
Executive Vice President, Chief Commercial Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

85 Wells Ave
NEWTON CENTER   MA   02459-3298

Phone: +1617.6580600

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.

SPONSORED STORIES